Immune globulin intravenous Alternatives Compared
| Immune globulin intravenous | Ultomiris (ravulizumab) | Rystiggo (rozanolixizumab) |
|
|---|
| Immune globulin intravenous | Ultomiris (ravulizumab) | Rystiggo (rozanolixizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Chronic Lymphocytic Leukemia, Dermatomyositis, Primary Immunodeficiency Syndrome, Immune Thrombocytopenia, Kawasaki Disease... View more |
Prescription only
Prescribed for Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria. Ultomiris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Myasthenia Gravis. Rystiggo may also be used for purposes not listed in this medication guide. |
Related suggestions Myasthenia Gravis
Popular comparisons
|
|||||||||||||||
| More about Immune globulin intravenous | More about Ultomiris (ravulizumab) | More about Rystiggo (rozanolixizumab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Immune globulin intravenous has an average rating of 7.8 out of 10 from a total of 28 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 7% reported a negative effect. |
Ultomiris has an average rating of 9.5 out of 10 from a total of 8 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Rystiggo has an average rating of 8.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Ultomiris side effects |
View all Rystiggo side effects |
|||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ultomiris prices |
View all Rystiggo prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Alyglo, Asceniv, Bivigam, Carimune NF, Flebogamma, Gammagard S/D, Gammaplex, Octagam, Panzyga, Privigen, Yimmugo View more |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
576 hours |
1192.8 hours |
N/A |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 107 drugs are known to interact with Immune globulin intravenous:
|
A total of 89 drugs are known to interact with Ultomiris:
|
A total of 302 drugs are known to interact with Rystiggo:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
December 21, 2018 |
June 26, 2023 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
|
||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.